ACADS: Enoyl-coenzyme A Reductase, Drug Target and Biomarker (G35)

Target Name: ACADS

NCBI ID: G35

ACADS

ACADS: Enoyl-coenzyme A Reductase, Drug Target and Biomarker

ACADS (Enoyl-coenzyme A reductase) is a enzyme that is involved in the citric acid cycle, also known as the Krebs cycle or tricarboxylic acid (TCA) cycle. This cycle is a central metabolism pathway that occurs in all eukaryotic cells and is responsible for generating energy in the form of ATP through a series of chemical reactions.

ACADS is a protein that is expressed in most cell types and is involved in the citric acid cycle. It is a key enzyme in the TCA cycle and is involved in the final step of the cycle, which is the production of ATP from ADP and phosphate.

One of the unique features of ACADS is its role in the production of ATP from ADP and phosphate. This is done through a process called phosphorylation, which involves the addition of a phosphate group to the ADP molecule. The phosphate group is then transferred to the ATP molecule, resulting in the production of ATP.

In addition to its role in ATP production, ACADS is also involved in the regulation of several cellular processes. For example, it is involved in the production of aromatic amino acids, which are important for the synthesis of DNA and RNA, as well as the production of certain neurotransmitters, such as dopamine.

ACADS is also involved in the detoxification of harmful substances, such as reactive oxygen species (ROS). ROS are free radicals that can damage cellular components and contribute to a variety of diseases, including cancer and neurodegenerative disorders. ACADS helps to protect cells from the harmful effects of ROS by participating in the production of antioxidants, such as superoxide dismutase.

As a drug target, ACADS has been identified as a potential target for several drugs, including those used to treat cancer, cardiovascular disease, and neurological disorders. For example, inhibitors of ACADS have been shown to have anti-tumor and anti-inflammatory effects, making them potential candidates for cancer treatment.

In addition to its potential as a drug target, ACADS is also an attractive biomarker for several diseases. For example, levels of ACADS have been shown to be elevated in the brains of individuals with Alzheimer's disease, a neurodegenerative disorder. Additionally, ACADS has been shown to be involved in the development and progression of certain neurological disorders, such as Parkinson's disease and Huntington's disease.

Overall, ACADS is a complex enzyme that is involved in a central metabolism pathway and has been identified as a potential drug target and biomarker. Further research is needed to fully understand its role in cellular processes and its potential as a therapeutic agent.

Protein Name: Acyl-CoA Dehydrogenase Short Chain

Functions: Short-chain specific acyl-CoA dehydrogenase is one of the acyl-CoA dehydrogenases that catalyze the first step of mitochondrial fatty acid beta-oxidation, an aerobic process breaking down fatty acids into acetyl-CoA and allowing the production of energy from fats (By similarity). The first step of fatty acid beta-oxidation consists in the removal of one hydrogen from C-2 and C-3 of the straight-chain fatty acyl-CoA thioester, resulting in the formation of trans-2-enoyl-CoA (By similarity). Among the different mitochondrial acyl-CoA dehydrogenases, short-chain specific acyl-CoA dehydrogenase acts specifically on acyl-CoAs with saturated 4 to 6 carbons long primary chains (PubMed:21237683, PubMed:11134486)

The "ACADS Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ACADS comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets